

Anatomy of a deal: Amgen and Nuevolution

On demand

Business Development Track

During the summer of 2019 Amgen acquired Nuevolution, a leading small molecule discovery platform, now operating as Amgen Research Copenhagen. With the acquisition of Nuevolution, Amgen obtained world-class DNA-encoded library capability and screening power to add unique capabilities to Amgen's small molecule drug discovery efforts, complementing the already broad research discovery expertise in human monoclonal antibodies and BiTE® molecules. Margaret Chu-Moyer and Ton Berkien will discuss why Amgen was looking for small molecule research capabilities, how the transaction came about and how the integration so far has delivered on the promise.

Participants

Host: Lucie Ellis - Executive Editor, In Vivo, Informa Pharma Intelligence

Guest: Ton Berkien - Director, Transactions, Business Development, Amgen

Guest: Margaret Chu-Moyer - VP, Research and Head of Chemistry, Characterization & Technology, Amgen

Emergence of novel therapeutic modalities in neurodegeneration

On demand

Therapeutic Track

Participants

Moderator: Christian Jung - Partner, Dementia Discovery Fund

Panelist: Sarah Cole - VP, Research and Development, TransSINE Therapeutics

Panelist: Tim Luker - VP, Emerging Technology & Innovation, Corporate Business Development, Eli Lilly & Company

Panelist: Rogier Rooswinkel - Principal, Forbion

Panelist: Beth Shafer - Sr. Director, CEI, R&D Business Development, Takeda Pharmaceuticals

What a pandemic has taught us about digital health

On demand

Biotech Ecosystem

Digital health is by no means new, but it has taken a pandemic to see a massive uptick in adoption of the way we deliver therapies and healthcare. This session will explore how COVID accelerated the digital trend and insights on how digital health will impact the future of care delivery and patient treatment.

Participants

Moderator: Jessica Shull - European Lead, Digital Therapeutics Alliance

Panelist: Regina Hodits - Managing Partner, Wellington Partners Life Sciences

Panelist: Douglas Lee - VP, Head Digital and Data Science, Business Development & Licensing, Bayer

Panelist: Austin Speier - Chief Strategy Officer, Click Therapeutics

Ride the new wave in Korea's pharmaceutical industry

On demand

Spotlight

This session describes the current landscape of immuno-oncology and regenerative medicine development in Korea and introduces the clinical trial infrastructure that supports these developments.

Participants

Moderator: Deok Cheol Kwon - President, KHIDI

Panelist: Lauren Lee - VP, Hanmi Pharma

Panelist: Antonio Lee - Managing Director, Medipost

Panelist: In Jin Jang - Director, Seoul National University Clinical Trials Center

Discovery of new species by high-throughput cultivation of anaerobic bacteria isolated from human gut samples

On demand

Microbiome Therapeutics

Participants

Speaker: Julian Riba - CSO, Cytene

In conversation with Hussein Manji

On demand

Business Development Track

Participants

Host: Paul Tunnah - Founder, pharmaphorum and Chief Content Officer and UK MD, Healthware Group

Guest: Hussein Manji - Global Head, Science for Minds, Johnson & Johnson

Changing the game for external innovation and partnering at Bayer, a conversation with Dr. Marianne De Backer

On demand

Business Development Track

In today's innovation ecosystem, the ability to forge strong partnerships is key to pharmaceutical companies in their pursuit of finding better or new treatment options for patients. On the occasion of BIO-Europe, Paul Tunnah speaks with Dr. Marianne De Backer, Bayer's executive responsible for strategy and external innovation. She shares insights about her first year at Bayer and her strategic vision for taking the company's engagement with current and potential partners to new heights. Adaptive and agile approach to deals and related decision-making are considered key. Dr. De Backer passionately elaborates on the purpose of leveraging breakthrough science and partnerships in ultimately making a difference for patients.

Participants

Host: Paul Tunnah - Founder, pharmaphorum and Chief Content Officer and UK MD, Healthware Group

Guest: Marianne De Backer - Member of Pharmaceuticals Executive Committee and Executive VP and Head of Strategy, Business Development & Licensing, Bayer AG

Genetically engineered microbial medicines (GEMMs) for the treatment of chronic diseases

On demand

Microbiome Therapeutics

- Developing a suite of synthetic biology tools for engineering highly abundant gut commensals
- Establishing an exclusive niche through rare carbohydrate utilization enables robust and controllable gut colonization of engineered strains
- The company's lead program to treat hyperoxaluria is nearing first-in-human studies

Participants

Speaker: Lane Weaver - Head, Business Development, Novome Biotechnologies

The future of biotech investment

On demand
Business Development Track

Participants

Moderator: Hubert Birner - Managing Partner, TVM Capital

Panelist: Johnston Erwin - VP, Corporate Business Development, Eli Lilly and Company

Panelist: Olivier Litzka - Partner, Andera Partners

Panelist: Amy Schulman - Managing Partner, Polaris Partners

Panelist: Otello Stampacchia - Managing Director, Omega Funds

Next directions in oncology

On demand
Therapeutic Track

Participants

Moderator: Luc Marengère - Managing Partner, TVM Capital

Panelist: Khatereh Ahmadi - Executive Director, Business Development and Licensing, MSD

Panelist: Aaron Chen - Senior Director, Global Business Development & Licensing, Oncology, Bayer

Panelist: Brendan Luu - VP, Head of Oncology Business Development, Merck KGaA

Panelist: Alain Thibault - Principal, TVM Capital

Collaboration Close up: Global Grassroots Innovation at Boehringer Ingelheim

On demand
Biotech Ecosystem

Participants

Host: Kevin Grogan - Managing Editor, Europe, Pharma Intelligence

Guest: Maria Antonietta Impagnatiello - Manager, Global Business Development and Licensing, SP Oncology, Boehringer Ingelheim

Guest: Ioannis Sapountzis - Corporate SVP, Business Development and Licensing, Boehringer Ingelheim

Guest: Mengtao Xiao - Senior Manager, Business Development and Licensing, Boehringer Ingelheim

Navigating Korea investment and ecosystem to connect global bio-pharma

On demand
Spotlight

- Introduction to Korea Investment Ecosystem for Bio-Pharma Sector
- Korea's Overseas Financial Investment: Readiness to Invest in Global Promising Bio-Pharma Companies
- Korea's Infrastructure Investment: Move-in Attractiveness for Global Promising Bio-Pharma Institutions
- Korea's Capital Market: Outstanding IPO opportunity for Global Promising Bio-Pharma Institutions
- Korea's R&D Investment: Co-R&D efforts between and among Leading Bio-Pharma Companies
- How Korea Investment Ecosystem will Impact the Global Bio-Pharma Industry

Participants

Moderator: Paul Yun - CEO, Ildong Pharmaceuticals and Chairman, KPBMA Global Affairs Committee

Panelist: Mahn Soon Hwang - Senior Managing Director, Korea Investment Partners (KIP)

Panelist: Se Joon Kim - Director General of Investment Inducement, Incheon Free Economic Zone (IFEZ)

Panelist: Min Suk Lee - Senior Manager, Korea Exchange (KRX)

Panelist: Kevin Kyung Hwa Huh - CEO, Korea Innovative Medicines Consortium (KIMCo)

Small molecule mining of human surrogate microbiome for therapeutics

On demand
Microbiome Therapeutics

- Technological breakthroughs now allow obtaining natural microbiome and interrogating the actual hidden chemistry along with the genomics
- Direct and indirect support for therapeutic opportunities emerging from natural environmental microbiome habitats is evidenced by drugs on the market or candidates in the pipeline and genomic and metabolic pathway overlap to various human microbiome

Participants

Speaker: Ross Youngs - CEO, Biosortia

Effective and efficient clinical trial strategies

On demand
Biotech Ecosystem

Participants

Moderator: Richie Pfeiffer - Senior Product Director, Innovation, Covance

Panelist: Geert-Jan Mulder - Managing Partner, Forbion

Panelist: Bray Patrick-Lake - Director, Strategic Partnerships, Evidation Health

Formulating an R&D vision at Servier

On demand
Business Development Track

Claude Bertrand talks with Andrew McConaghie about the reasons behind Servier's revitalization of their R&D strategy, the evolution of their therapeutic area focus and the unique perspective and culture that results from operating as a foundation.

Participants

Host: Andrew McConaghie - Senior Writer, Scrip

Guest: Claude Bertrand - SVP, Head of R&D, Servier

The repercussions of manufacturing requirements on cell and gene therapy deals

On demand
Therapeutic Track

Participants

Moderator: Jessica Carmen - Consultant, Pullan Consulting

Panelist: Brian Bronk - Head of Business Development and Licensing, Rare diseases, Neurosciences and Innovative Technologies Group, Sanofi

Panelist: Bernd Muehlenweg - SVP, Innovate Strategic Initiatives, Evotec

Panelist: Jens Vogel - SVP, Global Head of Biotech, Bayer Pharmaceuticals

Regulatory considerations for microbiome based therapeutics

On demand
Microbiome Therapeutics

As microbiome science has developed over the past few years, new perspectives have appeared in terms of health technology development. While translation from a therapeutic candidate into potential treatment is already ongoing, a wide diversity is observed in terms of product type and status (e.g. prebiotics, probiotics, postbiotics; but also food, grafts, LBPs, GMOs...). To date, there is no consolidated regulatory framework applicable encompassing all microbiome health technologies. As often when a new category of product emerges, whenever a dedicated regulatory framework seems to be required, collaboration between developers and regulators is key to design the corresponding technical and regulatory requirements that will support scientifically sound and pragmatic developments of safe and efficient therapeutics. Following the initial effort from national regulatory Authorities and multi-stakeholders initiatives from scientific institutions and industry, a clear need is identified for a more harmonized and globally recognized guidance as well as compatible regulatory processes for the microbiome product development and approval.

Participants

Moderator: Francois Gianelli - Director, CMC & Quality, Voisin Consulting Life Sciences

Speaker: Hervé Affagard - CEO, MaaT Pharma

Speaker: Paul Carlson - Principal Investigator, CBER at FDA

Speaker: Susan Stewart - Chief Regulatory Officer, Kaleido Biosciences

Strategic collaboration with clients and value enhancing partners: the why, what and how

On demand
Business Development Track

Federico Pollano discusses the key elements in Rentschler's approach to partnerships, highlighting new collaborations that have been made during the pandemic and Rentschler's focus on developing solutions in the rare disease space.

Participants

Host: Lucie Ellis - Executive Editor, In Vivo, Informa Pharma Intelligence

Guest: Federico Pollano - Senior VP, Business Development, Rentschler Biopharma SE

Rare diseases, patient data, and collaboration

On demand
Biotech Ecosystem

From identifying unmet needs to post-market follow-ups, patient data plays a major role in the development of therapeutics and curative treatments for rare diseases. This session will discuss the connections and collaborations that facilitate the effective use of patient data in developing drugs for rare diseases and the ways these collaboration models may impact the lifespan of treatments long after they are on the market.

Participants

Moderator: Craig Martin - President, Chief Engagement Officer, Rithm Health

Panelist: Mette Kirstine Agger - Managing Partner, Lundbeckfonden Ventures

Panelist: Nick Meade - Director of Policy, Genetic Alliance UK

Panelist: Anthony Philippakis - Chief Data Officer, Broad Institute

Panelist: Ian Winburn - Global Medical Team Lead, Haemophilia, Endocrine and IEM, Rare Diseases, Pfizer

Korea's Rising Bio Stars

On demand
Spotlight

This session features interviews with five of Korea's most exciting new companies including

- ILIAS BIO
- Aribio
- REDNVIA
- Immunomax
- NEXEL

Case study: Crowdsourcing to examine variation in microbiome standards

On demand
Microbiome Therapeutics

This session is a case study covering data collection and sequencing standardization.

Complex multispecies bacterial communities – is made more challenging by the high levels of diversity. Protocol steps, including extraction, purification, library preparation, and sequencing of genetic data from these communities may inadvertently introduce bias into the results. Through the Mosaic online microbiome analysis platform, we provided standard, identical microbiome samples to community volunteers, who extracted and sequenced the genetic material using their normal protocols. We collected the sequencing results and protocol data and analyzed them using a consistent bioinformatics pipeline to examine variation. We found that, while different extractions from the same samples cluster together, we observe significant shifts in the resulting organism abundance profiles; samples processed with the same, or similar, protocols showed greater similarity than identical biological samples processed using different protocol methods. These results suggest that protocol choices may introduce bias into microbiome experiments and must be carefully selected and maintained to ensure that comparisons of microbiome results are not skewed by underlying protocol changes.

Participants

Speaker: Sam Westreich - Microbiome Specialist and Bioinformatician, DNA Nexus

Partnering for impact: The importance of accessing external innovation for Novartis

On demand
Business Development Track

James Bradner, NIBR President, talks about the importance of partnering and how Novartis accesses external innovation to bring transformative medicines to patients

Participants

Guest: James Bradner - President, Novartis Institutes for BioMedical Research (NIBR)

New tools to conquer chronic kidney disease

On demand
Therapeutic Track

Participants

Moderator: Joseph Haas - Senior Writer, Pharma Intelligence

Panelist: Lars Erwig - VP of CVM Innovation, Johnson & Johnson Innovation

Panelist: Anne Fortier - Director, Discovery Biology, Vertex Pharmaceuticals

Panelist: Andrew King - Head of Renal Discovery and Translational Medicine, Chinook Therapeutics

Panelist: Olivier Radresa - VP, Nephrology, Evotec

In conversation with Sofinnova Partners' Graziano Seghezzi

On demand
Business Development Track

Participants

Host: Mike Ward - Global Head of Thought Leadership, DRG, part of Clarivate

Guest: Graziano Seghezzi - Partner, Sofinnova Partners

Patient-first discovery of bacterial biomarkers and live bacterial therapeutics for cancer immunotherapy

On demand
Microbiome Therapeutics

- New best-in-class study into how the gut microbiome impacts response to immune checkpoint inhibitors in advanced melanoma
- Precision mapping of this study using Microbiotica's platform has identified a pre-treatment microbiome signature highly predictive of response to anti-PD1 therapy across 4 independent melanoma studies
- A live bacterial therapeutic is being developed based on a consortium of strains associated with response to enhance the efficacy of anti-PD1 therapy in melanoma
- Analysis indicates microbiome associated with response varies between indications

Participants

Speaker: Mat Robinson - VP, Translational Biology, Microbiotica

How the right CDMO can support your product's path to clinic

On demand
Business Development Track

Companies developing new biologics have high expectations and the smallest details can determine long-term success. With the right service portfolio a CDMO can help streamline the path to clinic with customized and experienced based solutions to support pharmaceutical and biotech companies from preclinical development all the way through successful market launch.

Moderator: Deborah Gravelle, Content Marketing Coordinator, [EBD Group](#)

Interviewee: John Moore, Director of Global Clinical Business Development, [Vetter Pharma International](#)

[Watch Interview](#)

[Watch on YouTube](#)

AGC Biologics Capabilities and the introduction of Cell & Gene Therapy

On demand
Biotech Ecosystem

Participants

Speaker: Luca Alberici, AGC Biologics

Speaker: Bryson Kneller - VP Process Development, AGC Biologics

Machine Learning (ML) methods for biomarker identification for microbiome therapeutics, diagnostics and prognostics

On demand
Microbiome Therapeutics

- Understanding the power of ML in microbiome research
- How can microbiome ML development aid the identification of new biomarkers to novel microbiome-based therapeutics
- Good methodology for result's analysis that can be used for comparison across studies

Participants

Speaker: Marcus Claesson - Principal Investigator, University College Cork

From research to market: developing a biotech project in Wallonia

On demand
Biotech Ecosystem

In this fireside chat, Eric Halioua from Belgium-based PDC Line Pharma, discusses how the regional ecosystem has supported the company's development on an international scale.

Participants

Host: Andrew McConaghie - Senior Writer, Scrip

Guest: Eric Halioua - CEO, PDC Line Pharma

How to develop immunoregulatory pharmabiotics

On demand
Microbiome Therapeutics

- How to select the right microorganism to treat either hyper-immune disorders or cancer
- What are the effector molecules mediating the unique function of selected microorganism?
- Preclinical data of the effector molecules which recapitulate the whole bacteria

Participants

Speaker: Sin-Hyeog Im - Professor at POSTECH and CEO & Founder, ImmunoBiome Inc.

Health Equity: Addressing Health Disparities During Therapeutic Development

On demand
Biotech Ecosystem

In order to improve health outcomes for diverse populations, it's essential to begin by eliminating health disparities. With the spread of a pandemic that disproportionately affects communities of color and continued systemic inequality, BIO has launched the BIOEquality Agenda with a primary goal of promoting health equity. Learn from biopharma executives, clinicians, and patients about pathways to ensure that clinical trials are representative of patient populations and companies ensure access to prevention and treatment of diseases including COVID-19.

Participants

Moderator: Cartier Esham - Executive VP, Emerging Companies, Biotechnology Innovation Organization (BIO)

Panelist: Barbara Bierer - Faculty Director, Professor of Medicine, Harvard Medical School

Panelist: John Dwyer - President, Global Alzheimer's Platform Foundation

How COVID-19 is Bending the Curve on Vaccine Development and Manufacturing Norms

On demand
Business Development Track

Catalent announced its acquisition of the Anagni, Italy site from Bristol-Myers Squibb in June 2019 to enhance its late-stage and commercial capabilities for biologics, sterile injectables and oral solid dose products in Europe. As the COVID-19 virus began to spread into a global pandemic, the site quickly pivoted its efforts to support manufacturing hundreds of millions of doses of COVID-19 vaccine candidates in Europe.

In this interview, hear Mario Gargiulo, Catalent's Region President, Biologics, Europe describe the accelerated timelines and activities required to produce COVID-19 vaccine and therapeutic candidates in Anagni and our other global biologic sites.

Participants

Host: Dan Stanton - Editor and Founder, Bioprocess Insider, part of Informa Life Sciences' BioProcess International

Guest: Mario Gargiulo - Region President, Europe, Catalent Biologics

Using customized phage cocktail mixture to eradicate bacteria in chronic diseases

On demand
Microbiome Therapeutics

- Fusobacterium nucleatum bacteria eradication to treat colorectal cancer
- Using advanced synthetic biology to engineer phages
- Optimizing phage cocktail selection in vitro and in vivo for best activity

Participants

Speaker: Assaf Oron - Chief Business Officer, BiomX

Partnering in a pandemic world: in conversation with Martin Crook and Brian Cook

On demand
Business Development Track

Participants

Host: Linda Pullan - President, Pullan Consulting

Guest: Brian Cook - Executive Director, Oncology Transactions, Bristol-Myers Squibb

Guest: Martin Crook - Executive Director, Oncology Search and Evaluation, Bristol-Myers Squibb

Connecting clinic and commercial: Biopharma manufacturing

On demand
Biotech Ecosystem

Join this panel about how a new level of visibility for the biopharma manufacturing sector has changed relationships, investments, and capabilities. The discussion will explore not only the rapid adjustments made in response to the urgent concerns regarding vaccine production but also the transformations made to accommodate new modalities and considerations around global manufacturing capacity.

Participants

Moderator: Anthony Davies - Founder and CEO, Dark Horse Consulting Group

Panelist: José Castillo - CTO, Univercells

Panelist: Charles Christy - Head of Commercial Solutions, Ibex Solutions, Lonza

Symbiotic Drugs: Pharmaceutical control of the gut microbiome

On demand
Microbiome Therapeutics

- Small-molecule, non-antibiotic drugs that selectively target injury-causing bacterial activity
- Modulating xenobiotic metabolism by gut microbiota to improve the therapeutic window of cancer, pain and immunosuppressant medications

Participants

Speaker: Ward Peterson - CEO and President, Symberix

Expect more with Siegfried as your preferred partner

On demand
Business Development Track

Siegfried is your partner of choice in terms of development and manufacturing for your oral & sterile products. From our drug product network, currently consisting of a highly skilled team of more than 800 employees spread over four sites in Europe & US, we can offer you development, clinical & commercial supply services. Furthermore, two additional sites in Spain will be integrated into Siegfried's Drug Product Network beginning 2021. We can suit your needs along the several product stages, ranging from small-scale clinical up to large commercial scale manufacturing.

Moderator: Karina Marocco, Program Manager, Campaign Marketing, [EBD Group](#)

Interviewee: Laura de Miguel, PhD, Senior Manager Business Development Drug, [Siegfried AG](#)

Interviewee: Till Röhrich, PhD, Head R&D Oral Drug Product, [Siegfried AG](#)

Interviewee: Mario Vlastic, Senior Manager Business Development Drug Product, [Siegfried AG](#)

Interviewee: Sasa Kolaric, Manager Product & Business Development Drug Product, [Siegfried AG](#)

Interviewee: Olaf Wegener, Head R&D Sterile Drug Product, [Siegfried AG](#)

[Watch Interview](#)

[Watch on YouTube](#)

Designing scale up and manufacturing processes for microbiome therapeutics – end to end manufacturing issues – manufacturing and analytical challenges

On demand
Microbiome Therapeutics

Recent researches demonstrated that microbiota can sustain, promote and restore health. Novel therapeutic strategies promote health are therefore increasingly aiming at strains or consortia of strict anaerobic bacteria known as Next-generation Probiotics or live biotherapeutic products (LBP). The production of individual commercial probiotic strains such as Lactobacilli or Bifidobacteria is currently carried-out at large scale using batch fermentations. In contrast, production of strains of human microbiome origin has only been seldom investigated.

Lot of challenges remains today, and technology is lacking for implementation of human LBP manufacturing at scale. Indeed, most of these organisms are strict anaerobes, highly sensitive to environmental stresses encountered during processes, with complex, often unknown nutrient requirements, and limited or variable growth. This presentation will focus on innovative strategies to support the manufacturing of human microbiome related strains (single strains and/ or consortia) as well as on the practical and regulatory constraints associated with the CMC chapter.

Industrial manufacturing strategies are a critical step and a key challenge towards the commercialization of LBP which need to be addressed in the most efficient way.

Participants

Speaker: Alain Sourabié - Science Technology and Innovation Director, Procelys by Lesaffre

Cross-Border Partnering between Europe, US & China

On demand
Biotech Ecosystem

China, with a large patient population, has become the world's second-largest pharmaceutical market. With a rapidly increasing emphasis on innovative healthcare, Chinese investors and pharmaceutical companies are actively looking for global opportunities. This session will discuss cross-border collaborations between Europe, US & China, and opportunities and challenges for assets in different clinical trial stages to enter China.

Participants

Moderator: Echo Hindle-Yang - Founder and CEO, MSQ Ventures

Panelist: Robert Narquizian - Director, BioBasel Consulting and ChinaBio Capital

Panelist: Joan Shen - CEO, I-Mab Biopharma

Panelist: Shawn Singh - CEO, VistaGen

Panelist: Ed Zhang - Venture Partner, Hillhouse Capital Management

Commercialization opportunities within the human microbiome industry

On demand
Microbiome Therapeutics

- Therapeutics reaching the market: an overview from America and Canada
- What are the stages of microbiome therapeutics commercialization?
- Perceptions and misconceptions from the buyer at the end of the chain
- How can the industry interface with on-going research that findings from the lab can be transferred to the clinic?

Participants

Panelist: Jean-Francois Denault - CEO, Impacts CA

In conversation with Jeetendra Vaghjani

On demand
Biotech Ecosystem

Participants

Host: Julianna LeMieux - Science Writer, GEN: Genetic Engineering and Biotechnology New

Guest: Jeetendra Vaghjani - Director of Commercial Development, Mammalian and Microbial Development, Lonza

Microbiome industry breakthroughs – drug development plans

On demand
Microbiome Therapeutics

Participants

Speaker: Todd Krueger - Chief Executive Officer and President, AOBiome

Linking immunity and cancer to human microbiome

On demand
Microbiome Therapeutics

- How can cancer patients improve their outcomes with microbiome-based therapeutics?
- Oncology (MRx0518)

Participants

Speaker: Alex Stevenson - Chief Scientific Officer, 4d Pharma

Woman's health care and vaginal microbiota

On demand
Microbiome Therapeutics

- Phase II clinical trial in bacterial vaginosis
- Clinical trial results
- What does the future of vaginal microbiome holds?

Participants

Speaker: Peter Lee - Founder and Executive Chairman, Osel In

Strain-Level Profiling of the Gut Microbiome - A Novel Therapeutic Strategy to Prevent or Treat Sepsis

On demand
Microbiome Therapeutics

- How does sepsis change the gut microbiome in ways that affect health and behavior?
- What are the advantages of longitudinal strain-level profiling of the gut microbiome?

Participants

Speaker: Candice Brown - Principal Investigator, West Virginia University

SESSIONS

ON DEMAND SESSIONS -

BIO-Europe

October 26–29, 2020

Delivered Digitally
European Standard Time

Building patent portfolios protecting microbiome therapeutics: Recent guidance and best strategies

On demand
Microbiome Therapeutics

A presentation from J A Kemp will cover recent guidance and best strategies for building patent portfolios that protect microbiome therapeutics in a robust manner and thus provide valuable commercial assets. Bacterial products are far more complex than small molecule drugs and antibodies and so they require a tailored approach. It is also not yet settled how bacteria are best defined in patent claims, or what scope claims limited to bacterial strains might have. The presentation will review recent patent cases that provide some much-needed guidance and will discuss creative patent drafting strategies utilising input from technical and commercial teams to generate strong and flexible patent portfolios that fully support development of microbiome therapeutics.

Participants

Speaker: Ian MacLeod - Partner, Patent Attorney, J. A. Kemp

Specializing and investing in the microbiome spaces

On demand
Microbiome Therapeutics

- What is driving an increased interest in the microbiome industry?
- What are investors looking for?
- What are the latest investment trends?
- What can you do to stand out as a microbiome company when forging new partnerships?

Participants

Moderator: Denise Kelly - Investment Advisor, Seventure Partners

SCHEDULE

ON DEMAND SESSIONS -

BIO-Europe

October 26–29, 2020
Delivered Digitally
European Standard Time

TIME	BIOTECH ECOSYSTEM	BUSINESS DEVELOPMENT TRACK	MICROBIOME THERAPEUTICS	SPOTLIGHT	THERAPEUTIC TRACK
00:00	<p>On demand - What a pandemic has taught us about digital health</p> <p>On demand - Collaboration Close up: Global Grassroots Innovation at Boehringer Ingelheim</p>	<p>On demand - Anatomy of a deal: Amgen and Neuvolution</p> <p>On demand - In conversation with Hussein Manji</p> <p>On demand - Changing the game for external innovation and partnering at Bayer, a conversation with Dr. Marianne De Backer</p> <p>On demand - The future of biotech investment</p>	<p>On demand - Discovery of new species by high-throughput cultivation of anaerobic bacteria isolated from human gut samples</p> <p>On demand - Genetically engineered microbial medicines (GEMMs) for the treatment of chronic diseases</p>	<p>On demand - Ride the new wave in Korea's pharmaceutical industry</p>	<p>On demand - Emergence of novel therapeutic modalities in neurodegeneration</p> <p>On demand - Next directions in oncology</p>
01:00	<p>On demand - Effective and efficient clinical trial strategies</p> <p>On demand - Rare diseases, patient data, and collaboration</p>	<p>On demand - Formulating an R&D vision at Servier</p> <p>On demand - Strategic collaboration with clients and value enhancing partners: the why, what and how</p>	<p>On demand - Small molecule mining of human surrogate microbiome for therapeutics</p> <p>On demand - Regulatory considerations for microbiome based therapeutics</p>	<p>On demand - Navigating Korea investment and ecosystem to connect global bio-pharma</p>	<p>On demand - The repercussions of manufacturing requirements on cell and gene therapy deals</p>
02:00	<p>On demand - AGC Biologics Capabilities and the introduction of Cell & Gene Therapy</p>	<p>On demand - Partnering for impact: The importance of accessing external innovation for Novartis</p> <p>On demand - In conversation with Sofinnova Partners' Graziano Seghezzi</p> <p>On demand - How the right CDMO can support your product's path to clinic</p>	<p>On demand - Case study: Crowdsourcing to examine variation in microbiome standards</p> <p>On demand - Patient-first discovery of bacterial biomarkers and live bacterial therapeutics for cancer immunotherapy</p>	<p>On demand - Korea's Rising Bio Stars</p>	<p>On demand - New tools to conquer chronic kidney disease</p>

SCHEDULE

ON DEMAND SESSIONS -

BIO-Europe

October 26–29, 2020

Delivered Digitally
European Standard Time

TIME	BIOTECH ECOSYSTEM	BUSINESS DEVELOPMENT TRACK	MICROBIOME THERAPEUTICS	SPOTLIGHT	THERAPEUTIC TRACK
03:00	<p>On demand - From research to market: developing a biotech project in Wallonia</p> <p>On demand - Health Equity: Addressing Health Disparities During Therapeutic Development</p>	<p>On demand - How COVID-19 is Bending the Curve on Vaccine Development and Manufacturing Norms</p>	<p>On demand - Machine Learning (ML) methods for biomarker identification for microbiome therapeutics, diagnostics and prognostics</p> <p>On demand - How to develop immunoregulatory pharmabiotics</p>		
04:00	<p>On demand - Connecting clinic and commercial: Biopharma manufacturing</p>	<p>On demand - Partnering in a pandemic world: in conversation with Martin Crook and Brian Cook</p> <p>On demand - Expect more with Siegfried as your preferred partner</p>	<p>On demand - Using customized phage cocktail mixture to eradicate bacteria in chronic diseases</p> <p>On demand - Symbiotic Drugs: Pharmaceutical control of the gut microbiome</p>		
05:00	<p>On demand - Cross-Border Partnering between Europe, US & China</p> <p>On demand - In conversation with Jeetendra Vaghjiani</p>		<p>On demand - Designing scale up and manufacturing processes for microbiome therapeutics – end to end manufacturing issues – manufacturing and analytical challenges</p> <p>On demand - Commercialization opportunities within the human microbiome industry</p>		
06:00			<p>On demand - Microbiome industry breakthroughs – drug development plans</p> <p>On demand - Linking immunity and cancer to human microbiome</p>		

SCHEDULE

ON DEMAND SESSIONS -

BIO-Europe

October 26–29, 2020
Delivered Digitally
European Standard Time

TIME	BIOTECH ECOSYSTEM	BUSINESS DEVELOPMENT TRACK	MICROBIOME THERAPEUTICS	SPOTLIGHT	THERAPEUTIC TRACK
07:00			<p>On demand - Woman's health care and vaginal microbiota</p> <p>On demand - Strain-Level Profiling of the Gut Microbiome - A Novel Therapeutic Strategy to Prevent or Treat Sepsis</p>		
08:00			<p>On demand - Building patent portfolios protecting microbiome therapeutics: Recent guidance and best strategies</p> <p>On demand - Specializing and investing in the microbiome spaces</p>		

Abologix

On demand
Next Generation

Login and access [partneringONE](#) to watch the recording

Ab Studio, Inc.

On demand
Biotech

Indication: Antibodies

Login and access [partneringONE](#) to watch the recording

Actimed Therapeutics

On demand
Scrip's 10 To Watch

Indication: Oncology

Login and access [partneringONE](#) to watch the recording

Chugai Pharmaceutical Co., Ltd.

On demand
Midsize Pharma

[View company profile and watch recording](#)

Boehringer Ingelheim International GmbH

On demand
Large Pharma

[View company profile and watch recording](#)

Enable Therapeutics

On demand
Startup Slam

[View company profile and watch recording](#)

BioWin/Wallonia Export - Investment Agency

On demand
Regional Presentations

[View company profile and watch recording](#)

ImmTune Therapies

On demand
Startup Slam

[View company profile and watch recording](#)

Accure Therapeutics SL

On demand
Next Generation

Login and access [partneringONE](#) to watch the recording

KyNexus Medicine Development AB

On demand
Startup Slam

[View company profile and watch recording](#)

Accelerated Biosciences Corp.

On demand
Biotech

Indication: Cell and Gene Therapies

Login and access [partneringONE](#) to watch the recording

Adaptate Biotherapeutics

On demand
Scrip's 10 To Watch

Indication: Immuno-Oncology

Login and access [partneringONE](#) to watch the recording

Ildong Pharmaceutical

On demand
Midsize Pharma

[View company profile and watch recording](#)

Johnson & Johnson Innovation

On demand
Large Pharma

[View company profile and watch recording](#)

My Personal Therapeutics

On demand
Startup Slam

[View company profile and watch recording](#)

Health Holland

On demand
Regional Presentations

[View company profile and watch recording](#)

Acthera Therapeutics AG

On demand
Next Generation

Login and access [partneringONE](#) to watch the recording

Pear Bio

On demand
Startup Slam

[View company profile and watch recording](#)

Revibe Technologies

On demand
Startup Slam

[View company profile and watch recording](#)

Arctoris

On demand
Next Generation

Login and access [partneringONE](#) to watch the recording

Agilex Biolabs

On demand
Biotech

Indication: Drug Discovery and Development

Login and access [partneringONE](#) to watch the recording

Captor Therapeutics

On demand
Scrip's 10 To Watch

Indication: Drug Discovery and Development

Login and access [partneringONE](#) to watch the recording

Nippon Chemiphar

On demand
Midsize Pharma

[View company profile and watch recording](#)

Merck KGaA

On demand
Large Pharma

[View company profile and watch recording](#)

SaNOtize Research and Development Corp

00:30 - 00:35
Startup Slam

[View company profile and watch recording](#)

Swiss Biotech Association

On demand
Regional Presentations

[View company profile and watch recording](#)

Wildflower Biopharma, Inc.

On demand
Startup Slam

[View company profile and watch recording](#)

Bioelectronica

On demand
Next Generation

Login and access [partneringONE](#) to watch the recording

Ajinomoto Co., Inc.

On demand
Biotech

Indication: Antibodies

Login and access [partneringONE](#) to watch the recording

CellmAbs

On demand
Scrip's 10 To Watch

Indication: Oncology

Login and access [partneringONE](#) to watch the recording

Oasmia Pharmaceutical AB

On demand
Midsize Pharma

[View company profile and watch recording](#)

MSD

On demand
Large Pharma

[View company profile and watch recording](#)

BioStrand

On demand
Next Generation

Login and access [partneringONE](#) to watch the recording

bitBiome Inc

On demand
Next Generation

Login and access [partneringONE](#) to watch the recording

Akeso, Inc.

On demand
Biotech

Indication: Antibodies

Login and access [partneringONE](#) to watch the recording

CytoSeek

On demand
Scrip's 10 To Watch

Indication: Cell and Gene Therapies

Login and access [partneringONE](#) to watch the recording

Zambon

On demand
Midsize Pharma

[View company profile and watch recording](#)

Novartis Pharma

On demand
Large Pharma

[View company profile and watch recording](#)

Bowhead Health

On demand
Next Generation

Login and access [partneringONE](#) to watch the recording

amcure GmbH

On demand
Biotech

Indication: Oncology

Login and access [partneringONE](#) to watch the recording

Enesi Pharma Limited

On demand
Scrip's 10 To Watch

Login and access [partneringONE](#) to watch the recording

Pfizer

On demand
Large Pharma

[View company profile and watch recording](#)

Cognoptix

On demand
Next Generation

Login and access [partneringONE](#) to watch the recording

HapInScience Inc.

On demand
Next Generation

Login and access [partneringONE](#) to watch the recording

Anima Biotech

On demand
Biotech

Indication: Drug Discovery and Development

Login and access [partneringONE](#) to watch the recording

Ikarovec

On demand
Scrip's 10 To Watch

Indication: Cell and Gene Therapies

Login and access [partneringONE](#) to watch the recording

Roche

On demand
Large Pharma

[View company profile and watch recording](#)

Huen

On demand
Next Generation

Login and access [partneringONE](#) to watch the recording

Arcor Limited

On demand
Biotech

Indication: Drug Delivery

Login and access [partneringONE](#) to watch the recording

Pneumagen

On demand
Scrip's 10 To Watch

Indication: Infectious Diseases

Login and access [partneringONE](#) to watch the recording

Sanofi

On demand
Large Pharma

[View company profile and watch recording](#)

LifeMatrix Technologies AG

On demand
Next Generation

Login and access [partneringONE](#) to watch the recording

MyLife Technologies B.V.

On demand
Next Generation

Login and access [partneringONE](#) to watch the recording

Atriva Therapeutics

On demand
Biotech

Indication: Infectious Diseases

Login and access [partneringONE](#) to watch the recording

SOTIO

On demand
Scrip's 10 To Watch

Indication: Immuno-Oncology

Login and access [partneringONE](#) to watch the recording

Servier

On demand
Large Pharma

[View company profile and watch recording](#)

Neurix SA

On demand
Next Generation

Login and access [partneringONE](#) to watch the recording

Atrogi AB

On demand
Biotech

Indication: Diabetes

Login and access [partneringONE](#) to watch the recording

TreeFrog Therapeutics

On demand
Scrip's 10 To Watch

Indication: Cell and Gene Therapies

Login and access [partneringONE](#) to watch the recording

Pharmacorex

On demand
Next Generation

Login and access [partneringONE](#) to watch the recording

Rznomics Inc.

On demand
Next Generation

Login and access [partneringONE](#) to watch the recording

Aucentra Therapeutics

On demand
Biotech

Indication: Oncology

Login and access [partneringONE](#) to watch the recording

Teon Therapeutics, Inc.

On demand
Next Generation

Login and access [partneringONE](#) to watch the recording

Boehringer Ingelheim Biopharmaceuticals GmbH

On demand
Biotech

Indication: Contract Drug Development

Login and access [partneringONE](#) to watch the recording

Vertidiag

On demand
Next Generation

Login and access [partneringONE](#) to watch the recording

Wiregene

On demand
Next Generation

Login and access [partneringONE](#) to watch the recording

Boston Pharmaceuticals

On demand
Biotech

Indication: Translational Drug Development

Login and access [partneringONE](#) to watch the recording

CDR-Life

On demand
Biotech

Indication:

Login and access [partneringONE](#) to watch the recording

Cellestia Biotech AG

On demand
Biotech

Indication:

Login and access [partneringONE](#) to watch the recording

CENTOGENE GmbH

On demand
Biotech

Indication: Rare and Orphan Diseases

Login and access [partneringONE](#) to watch the recording

Codexis

On demand
Biotech

Indication: Drug Discovery and Development

Login and access [partneringONE](#) to watch the recording

CohBar Inc.

On demand
Biotech

Indication: Technologies and Tools

Login and access [partneringONE](#) to watch the recording

Daré Bioscience

On demand
Biotech

Indication: Women's Health

Login and access [partneringONE](#) to watch the recording

DOMAIN THERAPEUTICS

On demand
Biotech

Indication: Immuno-Oncology

Login and access [partneringONE](#) to watch the recording

Epsilogen Ltd

On demand
Biotech

Indication: Immuno-Oncology

Login and access [partneringONE](#) to watch the recording

eTheRNA Immunotherapies NV

On demand
Biotech

Indication: Immuno-Oncology

Login and access [partneringONE](#) to watch the recording

Eutilex

On demand
Biotech

Indication: Antibodies

Login and access [partneringONE](#) to watch the recording

Faron Pharmaceuticals Ltd

On demand
Biotech

Indication: Rare and Orphan Diseases

Login and access [partneringONE](#) to watch the recording

Helixmith Co., Ltd.

On demand
Biotech

Indication: Cell and Gene Therapies

Login and access [partneringONE](#) to watch the recording

HepaRegeniX GmbH

On demand
Biotech

Indication: Gastrointestinal

Login and access [partneringONE](#) to watch the recording

ILIAS Biologics

On demand
Biotech

Indication: Technologies and Tools

Login and access [partneringONE](#) to watch the recording

ImmuneCent Biotechnology

On demand
Biotech

Indication: Autoimmune/Inflammation

Login and access [partneringONE](#) to watch the recording

Immutep Limited

On demand
Biotech

Indication: Immuno-Oncology

Login and access [partneringONE](#) to watch the recording

InterAx Biotech

On demand
Biotech

Indication: Drug Discovery and Development

Login and access [partneringONE](#) to watch the recording

Jaguar Health, Inc.

On demand
Biotech

Indication: Gastrointestinal

Login and access [partneringONE](#) to watch the recording

Jubilant Therapeutics Inc

On demand
Biotech

Indication: Oncology

Login and access [partneringONE](#) to watch the recording

Juvabis AG

On demand
Biotech

Login and access [partneringONE](#) to watch the recording

MD Healthcare Inc.

On demand
Biotech

Indication: Microbiome

Login and access [partneringONE](#) to watch the recording

MedinCell

On demand
Biotech

Indication: Drug Delivery

Login and access [partneringONE](#) to watch the recording

Neumentum, Inc.

On demand
Biotech

Indication: Pain Management

Login and access [partneringONE](#) to watch the recording

Novago Therapeutics AG

On demand
Biotech

Indication: Antibodies

Login and access [partneringONE](#) to watch the recording

Oculus S.A.

On demand
Biotech

Indication: Ophthalmology

Login and access [partneringONE](#) to watch the recording

Orphagen Pharmaceuticals

On demand
Biotech

Indication: Oncology

Login and access [partneringONE](#) to watch the recording

OXURION NV

On demand
Biotech

Indication: Ophthalmology

Login and access [partneringONE](#) to watch the recording

PEPperPRINT GmbH

On demand
Biotech

Indication: Antibodies

Login and access [partneringONE](#) to watch the recording

RedHill Biopharma Ltd.

On demand
Biotech

Indication: Gastrointestinal

Login and access [partneringONE](#) to watch the recording

Refuge Biotech

On demand
Biotech

Indication: Cell and Gene Therapies

Login and access [partneringONE](#) to watch the recording

RhoVac AB

On demand
Biotech

Indication: Immuno-Oncology

Login and access [partneringONE](#) to watch the recording

Ryvü Therapeutics

On demand
Biotech

Indication: Oncology

Login and access [partneringONE](#) to watch the recording

Selvita

On demand
Biotech

Indication: Drug Discovery and Development

Login and access [partneringONE](#) to watch the recording

Shaperon

On demand
Biotech

Indication: Autoimmune/Inflammation

Login and access [partneringONE](#) to watch the recording

Standigm Inc.

On demand
Biotech

Indication: Drug Discovery and Development

Login and access [partneringONE](#) to watch the recording

TargImmune Therapeutics

On demand
Biotech

Indication: Immuno-Oncology

Login and access [partneringONE](#) to watch the recording

TOLLYS

On demand
Biotech

Indication: Immuno-Oncology

Login and access [partneringONE](#) to watch the recording

SESSIONS

COMPANY PRESENTATIONS -

BIO-Europe

October 26–29, 2020
Delivered Digitally
European Standard Time

ULTIMOVACS ASA

On demand
Biotech

Indication: Oncology

Login and access [partneringONE](#) to watch the recording

VAXIMM AG

On demand
Biotech

Indication: Oncology

Login and access [partneringONE](#) to watch the recording

Vivoryn Therapeutics AG

On demand
Biotech

Indication: CNS/Neurology

Login and access [partneringONE](#) to watch the recording

YSOPIA Bioscience (previously LNC Therapeutics)

On demand
Biotech

Indication: Microbiome

Login and access [partneringONE](#) to watch the recording

ZeClinics

On demand
Biotech

Indication: Technologies and Tools

Login and access [partneringONE](#) to watch the recording

SCHEDULE

COMPANY PRESENTATIONS -

BIO-Europe

October 26–29, 2020
Delivered Digitally
European Standard Time

TIME	BIOTECH	LARGE PHARMA	MIDSIZE PHARMA	NEXT GENERATION	REGIONAL PRESENTATIONS	SCRIP'S 10 TO WATCH	STARTUP SLAM
00:00	<p>On demand - Ab Studio, Inc.</p> <p>On demand - Accelerated Biosciences Corp.</p> <p>On demand - Agilex Biolabs</p> <p>On demand - Ajinomoto Co., Inc.</p>	<p>On demand - Boehringer Ingelheim International GmbH</p> <p>On demand - Johnson & Johnson Innovation</p> <p>On demand - Merck KGaA</p> <p>On demand - MSD</p>	<p>On demand - Chugai Pharmaceutical Co., Ltd.</p> <p>On demand - Ildong Pharmaceutical</p> <p>On demand - Nippon Chemiphar</p> <p>On demand - Oasmia Pharmaceutical AB</p>	<p>On demand - Abologix</p> <p>On demand - Accure Therapeutics SL</p> <p>On demand - Acthera Therapeutics AG</p> <p>On demand - Arctoris</p> <p>On demand - Bioelectronica</p> <p>On demand - BioStrand</p>	<p>On demand - BioWin/Waltonia Export - Investment Agency</p> <p>On demand - Health Holland</p> <p>On demand - Swiss Biotech Association</p>	<p>On demand - Actimed Therapeutics</p> <p>On demand - Adaptate Biotherapeutics</p> <p>On demand - Captor Therapeutics</p> <p>On demand - CellmAbs</p>	<p>On demand - Enable Therapeutics</p> <p>On demand - ImmTune Therapies</p> <p>On demand - KyNexis Medicine Development AB</p> <p>On demand - My Personal Therapeutics</p> <p>On demand - Pear Bio</p> <p>On demand - Revibe Technologies</p> <p>00:30 - SaNOtize Research and Development Corp</p> <p>On demand - Wildflower Biopharma, Inc.</p>
01:00	<p>On demand - Akeso, Inc.</p> <p>On demand - amcure GmbH</p> <p>On demand - Anima Biotech</p> <p>On demand - Arecor Limited</p>	<p>On demand - Novartis Pharma</p> <p>On demand - Pfizer</p> <p>On demand - Roche</p> <p>On demand - Sanofi</p>	<p>On demand - Zambon</p>	<p>On demand - bitBiome Inc</p> <p>On demand - Bowhead Health</p> <p>On demand - Cognoptix</p> <p>On demand - Hapl-Science Inc.</p> <p>On demand - Huen</p> <p>On demand - LifeMatrix Technologies AG</p>		<p>On demand - CytoSeek</p> <p>On demand - Enesi Pharma Limited</p> <p>On demand - Ikarovec</p> <p>On demand - Pneumagen</p>	

SCHEDULE

COMPANY PRESENTATIONS -

BIO-Europe
 October 26–29, 2020
 Delivered Digitally
 European Standard Time

TIME	BIOTECH	LARGE PHARMA	MIDSIZE PHARMA	NEXT GENERATION	REGIONAL PRESENTATIONS	SCRIP'S 10 TO WATCH	STARTUP SLAM
02:00	<p>On demand - Atriva Therapeutics</p> <p>On demand - Atrogi AB</p> <p>On demand - Aucentra Therapeutics</p> <p>On demand - Boehringer Ingelheim Biopharmaceuticals GmbH</p>	<p>On demand - Servier</p>		<p>On demand - MyLife Technologies B.V.</p> <p>On demand - Neurix SA</p> <p>On demand - Pharmacorex</p> <p>On demand - Rznomics Inc.</p> <p>On demand - Teon Therapeutics, Inc.</p> <p>On demand - Vertidiag</p>		<p>On demand - SOTIO</p> <p>On demand - TreeFrog Therapeutics</p>	
03:00	<p>On demand - Boston Pharmaceuticals</p> <p>On demand - CDR-Life</p> <p>On demand - Cellestia Biotech AG</p> <p>On demand - CENTOGENE GmbH</p>			<p>On demand - Wiregene</p>			
04:00	<p>On demand - Codexis</p> <p>On demand - CohBar Inc.</p> <p>On demand - Daré Bioscience</p> <p>On demand - DOMAIN THERAPEUTICS</p>						

SCHEDULE

COMPANY PRESENTATIONS -

BIO-Europe
 October 26–29, 2020
 Delivered Digitally
 European Standard Time

TIME	BIOTECH	LARGE PHARMA	MIDSIZE PHARMA	NEXT GENERATION	REGIONAL PRESENTATIONS	SCRIP'S 10 TO WATCH	STARTUP SLAM
05:00	<p>On demand - Epsilogen Ltd</p> <p>On demand - eTheRNA Immunotherapies NV</p> <p>On demand - Eutilex</p> <p>On demand - Faron Pharmaceuticals Ltd</p>						
06:00	<p>On demand - Helixmith Co., Ltd.</p> <p>On demand - HepaRegeniX GmbH</p> <p>On demand - ILIAS Biologics</p> <p>On demand - Immunecent Biotechnology</p>						
07:00	<p>On demand - Immutep Limited</p> <p>On demand - InterAx Biotech</p> <p>On demand - Jaguar Health, Inc.</p> <p>On demand - Jubilant Therapeutics Inc</p>						

SCHEDULE

COMPANY PRESENTATIONS -

BIO-Europe
 October 26–29, 2020
 Delivered Digitally
 European Standard Time

TIME	BIOTECH	LARGE PHARMA	MIDSIZE PHARMA	NEXT GENERATION	REGIONAL PRESENTATIONS	SCRIP'S 10 TO WATCH	STARTUP SLAM
08:00	<p>On demand - Juvabias AG</p> <p>On demand - MD Healthcare Inc.</p> <p>On demand - MedinCell</p> <p>On demand - Neumentum, Inc.</p>						
09:00	<p>On demand - Novago Therapeutics AG</p> <p>On demand - Oculis S.A.</p> <p>On demand - Orphagen Pharmaceuticals</p> <p>On demand - OXURION NV</p>						
10:00	<p>On demand - PEPper-PRINT GmbH</p> <p>On demand - RedHill Biopharma Ltd.</p> <p>On demand - Refuge Biotech</p> <p>On demand - RhoVac AB</p>						
11:00	<p>On demand - Ryvu Therapeutics</p> <p>On demand - Selvita</p> <p>On demand - Shaperon</p> <p>On demand - Standigm Inc.</p>						

SCHEDULE

COMPANY PRESENTATIONS -

BIO-Europe
 October 26–29, 2020
 Delivered Digitally
 European Standard Time

TIME	BIOTECH	LARGE PHARMA	MIDSIZE PHARMA	NEXT GENERATION	REGIONAL PRESENTATIONS	SCRIP'S 10 TO WATCH	STARTUP SLAM
12:00	<p>On demand - TargImmune Therapeutics</p> <p>On demand - TOLLYS</p> <p>On demand - ULTI-MOVACS ASA</p> <p>On demand - VAXIMM AG</p>						
13:00	<p>On demand - Vivoryon Therapeutics AG</p> <p>On demand - YSOPIA Bioscience (previously LNC Therapeutics)</p> <p>On demand - ZeClinics</p>						

SESSIONS

DAY 1 - LIVE SESSIONS - 26/10/2020

BIO-Europe

October 26–29, 2020

Delivered Digitally
European Standard Time

EIT Health Innostars Awards Grand Final

14:30 - 17:00

Additional Program

Join us at the InnoStars Awards Grand Final pitching contest with Europe's 10 best promising healthcare startups in 2020! During InnoStars Awards Grand Final, you will have the opportunity to meet the 10 finalists of EIT Health InnoStars Awards 2020 through pitches and 1:1 sessions.

About the InnoStars Awards program

InnoStars Awards helps start-ups from progressive European regions to validate their healthcare innovations, attract investors and ultimately shorten the time to get business ideas to the market. The program is open for micro and small enterprises, spin-offs and start-ups that already have a prototype or a Minimum Viable Product (MVP). All selected start-ups receive €25 000 smart money, individual mentoring for six months and the opportunity to participate in two bootcamps in Europe. After the four-month program, ten finalists are selected to participate in the InnoStars Awards final pitch contest in October, to compete for the three top prizes: an additional €25 000, €15 000 or €10 000 in funding. Beyond this, the start-ups have access to the support and potential investor connections available from EIT Health's Investor Network and EIT Health's Living Labs and Test Beds network.

Participants

Judge: Adam Broncel - General Partner, Biomed Innovation VC Fund

Judge: Filipa Fixe - Executive Board Member, Glintt

Judge: Ilona Kecskés - CEO, Capital Community

Presenter: Ana Maria Onica - Co-founder and CEO, Voxikids

Presenter: Madalin Margan - CEO, Oncochain

Presenter: Monica Piergiovanni - CEO, mEryLo'

Presenter: Andras Szilagyi - CEO, IT MEDicine

Presenter: Daniel Barbu - CEO, I'm Fine

Presenter: Robert Ackermann - CCO, Phoenix Orthosis

Presenter: Veronika Hudzikova - CEO, INOVUJ Face Rebab

Presenter: Gatis Mozoleskis - Co-founder, CellboxLabs

Presenter: Zajzon Bodó - CEO, Babyndex

Presenter: Dovydas Matuliaskas - CFO, Ligence

Presenter: Celso Almeida - CEO, Endobios

BIO-Europe Digital 2020 Networking: Long-lasting partnerships are like happy marriages

17:00 - 17:30

Networking

Fully Booked!!

Signing a deal with another company oftentimes feels like a wedding celebration. For months or years you are preparing, discussing every aspect, and are full of excitement when signatures are finally being exchanged. But then, the real work actually begins. As with every marriage, partnerships between two companies go through similar ups and downs over the years and no marriage or partnership is like another. Hence, there is also no secret recipe but experience shows that there are a few learnings that can be applied more broadly to ensure a partnership is as fruitful and lasting like a happy marriage.

Join our networking event to further build new connections and exchange tips on managing lasting partnerships, especially now in a fully virtual set-up. We look forward to your participation.

To give the virtual event the feeling of a real networking session, we encourage you to bring your own beverage!

Participants

Speaker: Urs Schleuniger - Global Head Alliance & Asset Management, Roche Pharma Partnering

Innovating the partnering future

17:30 - 18:30

Plenary

The coronavirus pandemic has resulted in innovation and collaboration round the globe at an unprecedented speed. In what other ways can innovation be supported in a crisis? Are there particular partnering models and collaboration frameworks that can support innovation across borders to meet universal unmet medical needs? What role do public private partnerships play in answering major global healthcare challenges? The plenary session at BIO-Europe will bring together participants in current collaborations to identify future directions for ecosystem innovation.

Participants

Moderator: Luke Timmerman - Founder and Editor, Timmerman Report

Panelist: Marianne De Backer - Member of Pharmaceuticals Executive Committee and Executive VP and Head of Strategy, Business Development & Licensing, Bayer AG

Panelist: J. Joseph Kim - President, CEO, Director, Inovio Pharmaceuticals

Panelist: Melanie Saville - Director, Vaccine Research and Development, CEPI (Coalition for Epidemic Preparedness Innovations)

Panelist: Paul Stoffels - Executive Vice President, Chief Scientific Officer, Johnson & Johnson

BIO-Europe Digital 2020 Networking: Introducing the 24/7 Café

On demand
Networking

The #newnormal provides us with a range of new opportunities.

We are introducing the truly global 24/7 Café. This initiative provides a serendipitous way to meet other conference delegates, it's open 24/7 and is a place to go to whenever you have time for a break.

Check-in to see if someone, somewhere else on this planet had just the same thought as you and is taking a break at the same time!

Take advantage of this informal mingling!

Log into partneringONE to access the 24/7 café on your Agenda.

SCHEDULE

DAY 1 - LIVE SESSIONS - 26/10/2020

BIO-Europe

October 26–29, 2020

Delivered Digitally
European Standard Time

TIME	ADDITIONAL PROGRAM	NETWORKING	PLENARY
14:00	14:30 - EIT Health Innostars Awards Grand Final		
15:00			
16:00			
17:00		<p>17:00 - BIO-Europe Digital 2020 Networking: Long-lasting partnerships are like happy marriages</p> <p>On demand - BIO-Europe Digital 2020 Networking: Introducing the 24/7 Café</p>	17:30 - Innovating the partnering future

SESSIONS

DAY 2 - LIVE SESSIONS - 27/10/2020

BIO-Europe

October 26–29, 2020

Delivered Digitally
European Standard Time

Innovative medical products – gene therapy and beyond

12:30 - 13:00
Spotlight

Participants

Moderator: Horst Domdey - Managing Director, BioM

What has COVID taught us so far?

14:00 - 14:30
Spotlight

Participants

Introduction: Katharina Gräfe - Scientific Officer, BIO.NRW

Moderator: Bernward Garthoff - CEO, BIO Clustermanagement NRW

Panelist: Thomas Schweins - Senior VP, Life Science Business Area, Qiagen

Panelist: Stephan Wnendt - CEO, MLM Medical Labs

Panelist: Holger Zimmermann - CEO, AiCuris

Panelist: Karl Ziegelbauer - Head of Open Innovation and Digital Tech, Bayer

Startup Slam

15:00 - 16:00
Spotlight

This exciting competition offers entrepreneurs a chance to virtually pitch their company at BIO-Europe Digital 2020. Selected companies will have the opportunity to create a five-minute video pitch, which will be hosted on the digital event site, and participate in a live feedback session. A jury of leading investors, pharma dealmakers and biotech business key opinion leaders will evaluate the pitches and select the winner during the live session. [Learn more here.](#)

Participants

Moderator: Madelaine Holden - Innovation Activation Senior Manager EMEA, Johnson & Johnson Innovation

Judge: Juliette Audet - Principal, Forbion

Judge: Leonildo Delgado - Manager, Innovation and Sourcing, BaseLaunch

Judge: Simon Kerry - Operating Partner, Advent Life Sciences

Judge: Elena Fernandez-Kleinlein - Head of JLABS EMEA, Johnson & Johnson Innovation

Judge: Sunil Shah - CEO, o2h Group

BIO-Europe Digital 2020 Networking: Introducing the 24/7 Café

On demand
Networking

The #newnormal provides us with a range of new opportunities.

We are introducing the truly global 24/7 Café. This initiative provides a serendipitous way to meet other conference delegates, it's open 24/7 and is a place to go to whenever you have time for a break.

Check-in to see if someone, somewhere else on this planet had just the same thought as you and is taking a break at the same time!

Take advantage of this informal mingling!

Log into partneringONE to access the 24/7 café on your Agenda.

BiotechBikers Live Ride and Networking Hour

18:30 - 19:00
Networking

Attention Peloton #BiotechBikers! Together with Morrie Ruffin, Martina Molsbergen and Ian Wisenberg, EBD's Anna Chrisman will be hosting the first ever #BiotechBikers Live Ride and Networking Hour during BIO-Europe next week!

Update: The live class was cancelled, therefore we've selected an on demand class and tried to find a playlist that resembled our usual Tuesday night dance party at BIO-Europe.

Instructions:

- In your Peloton Profile, select the tag #BiotechBikers and set your location to BIO-Europe
- **UPDATED:** Select the class (search for Leanne's 90s ride from 7/7/20 or bookmark https://members.onepeloton.com/classes/cycling?utm_source=ios_app&utm_medium=in_app&modal=classDetailsModal&classId=ee787068c1f446bfdb1e8f52a)
- Show up: Tuesday Oct 27 at 18:30 CET/1.30 PM Eastern, select the "here now" view and press start exactly at the 1:30 PM Eastern.
- Ride, sweat and let the High Fives fly!

At 19.10 CET/14.10 Eastern, join the "watercooler networking session" in the BIO-Europe Virtual Hub. No time to shower - we're keeping it real! Brag about your PRs, gossip about our favorite instructors and maybe even set up future group rides.

SCHEDULE

DAY 2 - LIVE SESSIONS - 27/10/2020

BIO-Europe

October 26–29, 2020
Delivered Digitally
European Standard Time

TIME	NETWORKING	SPOTLIGHT
12:00		12:30 - Innovative medical products – gene therapy and beyond
13:00		
14:00		14:00 - What has COVID taught us so far?
15:00		15:00 - Startup Slam
16:00		
17:00	On demand - BIO-Europe Digital 2020 Networking: Introducing the 24/7 Café	
18:00	18:30 - BiotechBikers Live Ride and Networking Hour	

#BiotechBiker Zwift Ride

06:00 - 06:45
Networking

Want another chance to meet up with the #BiotechBiker community? Join us for a virtual sunrise Zwift group ride in France!

Here's how to join:

Before:

- Follow ride leader Mark Farmery on the Zwift Companion App (zwift.com)
- You'll receive an invitation for the BIO-Europe 2020 Zwift Meetup, accept and you're all set

On the day:

- Log in to Zwift, follow the Meetup instructions, fill your bidon and be ready on Wednesday October 28th at 06.00 CET for 45 min ride at an easy pace on the Roule Ma Poule course in France

Ride on!

EIT Health Headstart : COVID-19 focus

14:00 - 14:30
Additional Program

The [EIT Health Headstart](#) brings together top-tier start-ups addressing significant health challenges facing Europe today. Join the virtual Grand Final of this well-known competition and meet 15 specially selected teams who are developing revolutionary healthcare products and solutions. They will compete for the pool prize, which is 80 000 €.

EIT Health's Headstart Programme accelerates the market launch of selected healthcare start-ups through grants as well as support with networking and developing a project plan. Mentored by EIT Health's regional teams, the programme offers support to the companies as they navigate the steps required to bring their solution to market including, crucially, verification of the clinical, patient or system need for the product or service.

The Top 15 start-ups that have reached the Finals are from Southern, Central and Eastern Europe. The teams have developed products and services in areas such as cancer, geriatrics, ophthalmology, wound care, women's health, genetic and neurological conditions, cardiology and digital tools to assist healthcare services in the management of patients as well as research and development.

This year, Headstart is supplemented by two special programmes, COVID-19 and NAM.

COVID-19 Cohort

In 2020, EIT Health expanded the scope of Headstart to assist in the immediate need for solutions to combat COVID-19, and has selected a specific group of start-ups that will develop products and services that will help Europe to contain, treat and manage the disease.

More: <https://eithealth.eu/project/headstart/>

Participants

Presenter: **Giordano Botta** - CEO, Allelica

Presenter: **Vasileia Chatzistergiou** - Co-founder, Medical Data and Communication Manager, Booking Clinic

Presenter: **Giuseppe Cordella** - Founder and CEO, Drivesec

Presenter: **Sergey Jakimov** - Co-founder and CEO, Longgenesis

Fireside chat screening with President of Novartis Institute of Biomedical Research (NIBR) and Live Q&A with Novartis Partnering

15:00 - 15:30
Networking

Join Nigel Sheail, Global Head Mergers and Acquisitions and Business Development and Licensing for a screening of the On Demand fireside chat with James Bradner, President of the Novartis Institutes for BioMedical Research, followed by a live Q&A, where Nigel will answer questions from the audience.

Participants

Host: **Nigel Sheail** - Global Head, Mergers & Acquisitions and Business Development & Licensing, Novartis

A Day in the life of experienced dealmakers

16:00 - 17:00
Plenary

Participants

Moderator: **Evonne Sepsis** - Founder and Managing Director, ESC Advisors

Moderator: **Anton Gueth** - Managing Director, EVOLUTION Life Science Partners

Panelist: **Marc de Garidel** - Chairman, Ipsen

Panelist: **Stelios Papadopoulos** - Chairman of the Board, Biogen, Exelixis, Regulus Therapeutics

Panelist: **James Sabry** - Global Head, Pharma Partnering, Roche

Live Q&A with AGC

17:00 - 17:30
Networking

Participants

Host: **Luca Alberici**, AGC Biologics

Host: **Bryson Kneller** - VP Process Development, AGC Biologics

In conversation with Philippe Lopes-Fernandes, Executive Vice President and CBO, IPSEN

17:30 - 18:15

Plenary

Join this live chat between Anna Chrisman, President Informa Connect Life Sciences and Philippe Lopes-Fernandes, Executive Vice President and CBO, IPSEN.

As communities around the world continue to work to control the spread of COVID-19 and keep people safe, we are confronted with the need to find new ways to come together to advance our pipelines and deliver transformational therapies to patients. Major business development and partnering meetings will continue to be virtual into 2021, and it is increasingly likely that the virtual world will continue beyond 2021 and even COVID. Philippe Lopes-Fernandes has always been willing to think differently about BD and try new approaches to making connections. He did this recently on a personal level, changing companies in the middle of the pandemic. Now the Executive Vice President and Chief Business Officer of Ipsen, Philippe will join us from his home office to talk about virtual deal making, transitioning jobs during a pandemic and his thoughts on what type of deals to expect from the industry in 2021.

Stay on for a lively networking session immediately following to chat with Anna and Philippe about Covid, its impact on our lives, #biotechbikers or #biotechrunners and whatever else comes to mind.

Participants

Guest: Philippe Lopes-Fernandes - Executive Vice President and CBO, IPSEN

Host: Anna Chrisman - Managing Director Pharma and Life Sciences, Informa Connect

BIO-Europe Digital 2020 Networking: Introducing the 24/7 Café

On demand
Networking

The #newnormal provides us with a range of new opportunities.

We are introducing the truly global 24/7 Café. This initiative provides a serendipitous way to meet other conference delegates, it's open 24/7 and is a place to go to whenever you have time for a break.

Check-in to see if someone, somewhere else on this planet had just the same thought as you and is taking a break at the same time!

Take advantage of this informal mingling!

Log into partneringONE to access the 24/7 café on your Agenda.

SCHEDULE

DAY 3 - LIVE SESSIONS - 28/10/2020

BIO-Europe

October 26–29, 2020

Delivered Digitally
European Standard Time

TIME	ADDITIONAL PROGRAM	NETWORKING	PLENARY
06:00		06:00 - #BiotechBiker Zwift Ride	
07:00			
08:00			
09:00			
10:00			
11:00			
12:00			
13:00			
14:00	14:00 - EIT Health Headstart : COVID-19 focus		
15:00		15:00 - Fireside chat screening with President of Novartis Institute of Biomedical Research (NIBR) and Live Q&A with Novartis Partnering	
16:00			16:00 - A Day in the life of experienced dealmakers
17:00		17:00 - Live Q&A with AGC On demand - BIO-Europe Digital 2020 Networking: Introducing the 24/7 Café	17:30 - In conversation with Philippe Lopes-Fernandes, Executive Vice President and CBO, IPSEN

SESSIONS

DAY 4 - LIVE SESSIONS - 29/10/2020

BIO-Europe

October 26–29, 2020

Delivered Digitally

European Standard Time

BIO-Europe Digital 2020 Networking: Introducing the 24/7 Café

On demand
Networking

The #newnormal provides us with a range of new opportunities.

We are introducing the truly global 24/7 Café. This initiative provides a serendipitous way to meet other conference delegates, it's open 24/7 and is a place to go to whenever you have time for a break.

Check-in to see if someone, somewhere else on this planet had just the same thought as you and is taking a break at the same time!

Take advantage of this informal mingling!

Log into partneringONE to access the 24/7 café on your Agenda.

BIO-Europe Digital 2020 Networking: Long-lasting partnerships are like happy marriages

10:00 - 10:30
Networking

Fully Booked!

Signing a deal with another company oftentimes feels like a wedding celebration. For months or years you are preparing, discussing every aspect, and are full of excitement when signatures are finally being exchanged. But then, the real work actually begins. As with every marriage, partnerships between two companies go through similar ups and downs over the years and no marriage or partnership is like another. Hence, there is also no secret recipe but experience shows that there are a few learnings that can be applied more broadly to ensure a partnership is as fruitful and lasting like a happy marriage.

Join our networking event to further build new connections and exchange tips on managing lasting partnerships, especially now in a fully virtual set-up. We look forward to your participation.

To give the virtual event the feeling of a real networking session, we encourage you to bring your own beverage!

Fully Booked!

Participants

Speaker: Urs Schleuniger - Global Head Alliance & Asset Management, Roche Pharma Partnering

EIT Health Headstart : Cohort A

11:00 - 12:00
Additional Program

The [EIT Health Headstart](#) brings together top-tier start-ups addressing significant health challenges facing Europe today. Join the virtual Grand Final of this well-known competition and meet 15 specially selected teams who are developing revolutionary healthcare products and solutions. They will compete for the pool prize, which is 80 000 €.

EIT Health's Headstart Programme accelerates the market launch of selected healthcare start-ups through grants as well as support with networking and developing a project plan. Mentored by EIT Health's regional teams, the programme offers support to the companies as they navigate the steps required to bring their solution to market including, crucially, verification of the clinical, patient or system need for the product or service.

The Top 15 start-ups that have reached the Finals are from Southern, Central and Eastern Europe. The teams have developed products and services in areas such as cancer, geriatrics, ophthalmology, wound care, women's health, genetic and neurological conditions, cardiology and digital tools to assist healthcare services in the management of patients as well as research and development.

This year, Headstart is supplemented by two special programmes, COVID-19 and NAM.

More: <https://eithealth.eu/project/headstart/>

Participants

Presenter: Sebastião van Uden - CEO, Bac3Gel

Presenter: Sara Lobo - Co-founder and CMO, C-mo Medical Solutions

Presenter: Cornel Amariei - Founder, DOTLUMEN

Presenter: Massimiliano Clamer - Founder and President, IMMAGINA BioTechnology

Presenter: Alfonso Maria Ponsiglione - Co-founder and COO, Kyme Nanolmaging

Presenter: David Breitenbach - Co-founder, Sineko Global

Presenter: Ivan Porro - Founder and CEO, SurgiQ

Presenter: Daniele Conti - Co-founder and CEO, SYNDIAG

EIT Health Headstart : Cohort B

15:30 - 16:15
Additional Program

The [EIT Health Headstart](#) brings together top-tier start-ups addressing significant health challenges facing Europe today. Join the virtual Grand Final of this well-known competition and meet 15 specially selected teams who are developing revolutionary healthcare products and solutions. They will compete for the pool prize, which is 80 000 €.

EIT Health's Headstart Programme accelerates the market launch of selected healthcare start-ups through grants as well as support with networking and developing a project plan. Mentored by EIT Health's regional teams, the programme offers support to the companies as they navigate the steps required to bring their solution to market including, crucially, verification of the clinical, patient or system need for the product or service.

The Top 15 start-ups that have reached the Finals are from Southern, Central and Eastern Europe. The teams have developed products and services in areas such as cancer, geriatrics, ophthalmology, wound care, women's health, genetic and neurological conditions, cardiology and digital tools to assist healthcare services in the management of patients as well as research and development.

This year, Headstart is supplemented by two special programmes, COVID-19 and NAM.

NAM Healthy Longevity Global Competition

In 2020, Headstart offers an added opportunity for ventures with a focus on physical, mental, and social well-being for people as they age, joining the U.S. NAM Healthy Longevity Global Competition. The Competition includes a three-tiered structure of awards: a first phase of Catalyst Awards, a second phase of Accelerator Award, and a third Grand Prize phase. Through Headstart, EIT Health holds a Catalyst Award competition, participating in the first phase of the Global Competition.

More: <https://eithealth.eu/project/headstart/>

Participants

Presenter: Eugene Nayshtetik - Founder and Managing Partner, Lorton Investments - SenceBand

Presenter: Katarzyna Zimoląg - CEO, i-Care

Presenter: Riccardo Piccioli - Co-founder and CEO, Mysurable

SESSIONS

DAY 4 - LIVE SESSIONS - 29/10/2020

BIO-Europe

October 26–29, 2020

Delivered Digitally
European Standard Time

COVID-19 therapeutics: Modality, efficacy and implications for access

17:00 - 18:00

Plenary

As COVID-19 infections spread around the world, companies moved swiftly to test many of the products in their pipelines. This has led to a broad array of novel approaches to treating patients infected with the virus, from antibodies that could be given as prevention to treatments that help reduce the impact of the cytokine storm or Acute Respiratory Distress Syndrome (ARDS). This panel of top scientists and industry leaders will share information on the development of these non-vaccine treatment options and address the challenges around achieving global access to these products.

The session will also feature an update on the landscape of therapeutics and vaccines in development for COVID-19.

Participants

Moderator: Phyllis Arthur - VP, Infectious Disease and Vaccine Policy, Biotechnology Innovation Organization (BIO)

Speaker: David Thomas - VP, Industry Research and Analysis, Biotechnology Industry Organization (BIO)

Panelist: Richard Marsden - CEO, Synairgen

Panelist: Neil Mulcock - VP, Government Affairs, EMEA, Gilead Sciences

Panelist: Kylie O'Keefe - VP, Global Commercial Strategy, PTC Therapeutics

Panelist: Gregg Szabo - VP and Commercial Leader, Virology/Immunology, MSD

SCHEDULE

DAY 4 - LIVE SESSIONS - 29/10/2020

BIO-Europe

October 26–29, 2020

Delivered Digitally
European Standard Time

TIME	ADDITIONAL PROGRAM	NETWORKING	PLENARY
09:00		On demand - BIO-Europe Digital 2020 Networking: Introducing the 24/7 Café	
10:00		10:00 - BIO-Europe Digital 2020 Network- ing: Long-lasting partnerships are like happy marriages	
11:00	11:00 - EIT Health Headstart : Cohort A		
12:00			
13:00			
14:00			
15:00	15:30 - EIT Health Headstart : Cohort B		
16:00			
17:00			17:00 - COVID-19 therapeutics: Modality, efficacy and implications for access